Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Oct 25 - Oct 30
Structure's GLP-1 Pill Could Be Big, But Trial Results Will Confirm Structure Therapeutics Today GPCR Structure Therapeutics $48.36 +0.32 (+0.67%) As of 08/3/2026 04:00 PM Eastern 52-Week Range $15.80 $94.90 Price Target $110.55 Shares of Structure Therapeutics NASDAQ: GPCR have far outperformed both of the companies above in the last year, rising by over 150% during that time as investors have grown enthusiastic about aleniglipron, the firm's GLP-1 agonist candidate
That said, clinical trial results in Parkinsons disease have been mixed
Weve had Ozempic Face, Ozempic Butt, and now, its Ozempic Vulva
2-4 Weeks : Boosted immune function and NK cell activity
Two things change everything: Protein
US$ 21.91
US$ 27.70
US$ 24.71
